Neuroproteomic tools for battling Alzheimer's disease.

about

A Precision Medicine Initiative for Alzheimer's disease: the road ahead to biomarker-guided integrative disease modeling.The Emerging Role of Proteomics in Precision Medicine: Applications in Neurodegenerative Diseases and Neurotrauma.

P2860

Q30235315-E686893F-F214-474E-9EAF-086D93371C50 Q38368569-F284D58B-943E-4E05-BB4A-F6E1D20A2BF4

P2860

Neuroproteomic tools for battling Alzheimer's disease.

Item

http://www.wikidata.org/entity/Q38955684

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Neuroproteomic tools for battling Alzheimer's disease.

@en

type

Item

label

Neuroproteomic tools for battling Alzheimer's disease.

@en

prefLabel

Neuroproteomic tools for battling Alzheimer's disease.

@en

P1476

Neuroproteomic tools for battling Alzheimer's disease.

@en

P2093

Timothy D Veenstra

http://www.w3.org/2001/XMLSchema#string

P2860

The proteolytic processing of the amyloid precursor protein gene family members APLP-1 and APLP-2 involves alpha-, beta-, gamma-, and epsilon-like cleavages: modulation of APLP-1 processing by n-glycosylation

Monetary costs of dementia in the United States

Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits

Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides.

The role of apolipoprotein E in Alzheimer's disease.

Homodimerization Protects the Amyloid Precursor Protein C99 Fragment from Cleavage by γ-Secretase.

Neuropsychiatric Symptoms in Parkinson's Disease Dementia Are More Similar to Alzheimer's Disease than Dementia with Lewy Bodies: A Case-Control Study.

Stable isotope labeling tandem mass spectrometry (SILT) to quantify protein production and clearance rates.

Regulation of global gene expression and cell proliferation by APP

A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans.

P304

2847-2853

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PMIC.201600211

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-09-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27633846

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

Neuroproteomic tools for battling Alzheimer's disease.

about

P2860

P2860

Neuroproteomic tools for battling Alzheimer's disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921